NDA 220018 · Gilead Sciences INC
Yeztugo
Lenacapavir, Lenacapavir Sodium · Subcutaneous
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 18, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
15 Phase 3, 12 recruiting
FAERS reports
506
127 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION Individuals must be tested for HIV-1 infection prior to initiating YEZTUGO, and with each subsequent injection of YEZTUGO, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of YEZTUGO by individuals with undiagnosed HIV-1 infection. Do not initiate YEZTUGO unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving YEZTUGO must transition to a complete HIV-1 treatment regimen [see Dosage and Administration (2.1) , Contraindications (4) , Warnings and Precautions (5.1 , 5.2) ]. WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION See full prescribing...
What it is approved for
From the label in effect Aug 11, 2026.
YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. YEZTUGO, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO. ( 1 )
Mechanism: YEZTUGO is an HIV-1 antiretroviral agent with long-acting properties [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2025 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelBreakthrough therapyLabelLetterReview
2 products under this application
- YEZTUGO · LENACAPAVIR 463.5MG/1.5ML(309MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- YEZTUGO · LENACAPAVIR SODIUM EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lenacapavir" as an intervention, any sponsor and status, largest first.
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04925752 · 3,292 participants · Start Jun 28, 2021 · Primary completion Aug 21, 2024
Drug: Oral Lenacapavir (LEN); F/TDF and 5 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 93 sites in all
Oswaldo Cruz FoundationAcademic, hospital or other
NCT07497594 · 1,500 participants (planned) · Start Feb 3, 2026 · Primary completion Feb 2029
Drug: Lenacapavir long-acting; Tenofovi-Emtricitabine (TDF/FTC) tablet · For: Contact With or Exposure to Human Immunodeficiency Virus
Sites: Manaus, Brazil; Salvador, Brazil; Nova Iguaçu, Brazil · 8 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630286 · 609 participants · Start Oct 9, 2024 · Primary completion Apr 17, 2026
Drug: ISL/LEN; B/F/TAF and 2 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 106 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630299 · 600 participants (planned) · Start Oct 8, 2024 · Primary completion Apr 23, 2026
Drug: ISL/LEN; Antiretroviral Combinations · For: HIV-1-Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site discharge149
- injection site pain141
- injection site nodule113
- injection site erythema43
- injection site mass37
- injection site swelling24
- injection site cellulitis17
- loss of consciousness16
- injection site bruising15
- injection site reaction14
- syncope13
- nausea12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 367 |
| 2026 | 138 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
Jogiraju V, Pawar P, Yager J, et al. · Lancet 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Lenacapavir as pre-exposure prophylaxis for HIV prevention.
Ebrahim S, Gloeck N, Adam Z, et al. · Cochrane Database Syst Rev 2026 · Systematic Review, Meta-Analysis
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Gupta SK, Berhe M, Crofoot G, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.